Data may be delayed — last successful sync 2026-09-26 (18 days ago). Figures reflect the most recent completed ingest.
Company profile
BioELife Corp.
OTC: LITH · Healthcare · Drug Manufacturers - Specialty & Generic
#1162 of 1,417 Healthcare companies by revenue
EA Score
——FH —DQ 14GM —SS 24
v0.1 · 25/100 weight · pillars only
↑ listing tenure, balance-sheet leverage · ↓ workforce scale, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$337.0k
Employees
1
as of 2026-08-31
Market cap
$941
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02013
Net income-$337.0k-$337.0k2018
Operating income-$73.7k-$73.7k2018
Total assets$140.0k$140.0k2018
Liabilities$321.7k$321.7k2016
Equity-$325.2k-$325.2k2018
Revenue trend
FY2011 – FY2013 · USD
FY11
FY11
FY12
FY13
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is BioELife Corp.’s revenue?
BioELife Corp. booked $0 in FY2013 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Grupo International Inc.——Omnimmune Holdings, Inc.——TetraLogic Pharmaceuticals Corporation——North Bud Farms Inc.——OncoSec Medical Incorporated——Verde Science, Inc.——Neighbors
Orange →Key facts
CEOMichael Terpin
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersSeal Beach, CA
ExchangeOTC: LITH
Employees1
IPO date2009-08-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.